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Abstract
Improved diagnostic methods are needed for bronchiolitis obliterans syndrome (BOS), a serious 
complication after allogeneic hematopoietic cell transplantation (HCT) and lung transplantation. 
For proteins candidate discovery, we compared plasma pools from HCT transplantation recipients 
with: BOS at onset (n=12), pulmonary infection (n=16), chronic graft-versus-host disease without 
pulmonary involvement (n=15), and no chronic complications post-HCT (n=15). Pools were 
labeled with different tags [isobaric Tags for Relative and Absolute Quantification (iTRAQ)], and 
two software tools identified differentially expressed proteins (≥1.5-fold change). Candidate 
proteins were further selected using a six-step computational biology approach. The diagnostic 
value of the lead candidate, matrix metalloproteinase-3 (MMP-3), was evaluated by ELISA in 
plasma of a verification cohort (n=112) with and without BOS following HCT (n=76) or lung 
transplantation (n=36). MMP-3 plasma concentrations differed significantly between patients with 
and without BOS (AUC=0.77). Thus, MMP-3 represents a potential non-invasive blood test for 
diagnosis of BOS.
 1. Introduction
Bronchiolitis obliterans syndrome (BOS) occurs following allogeneic hematopoietic cell 
transplantation (HCT) when a transplant donor’s immune system attacks lung tissue, 
ultimately leading to fibrosis of small airways and symptoms of respiratory insufficiency. 
BOS is a manifestation of pulmonary chronic graft-versus-host disease (cGVHD) and is 
associated with high morbidity and mortality (1–6). A similar syndrome occurs in lung 
transplantation recipients. Studies in human lung transplantation recipients and animal 
models suggest that BOS is initiated by immune recognition of foreign antigens in the lung 
epithelia, leading to inflammation and fibroproliferation within the small airways 
(bronchioles), which further results in air trapping and pulmonary insufficiency (1, 7–13). 
Although little is known about the precise mechanisms underlying the initiation or 
progression of BOS, perturbations in cellular, cytokine, and protein profiles have been 
documented in lung tissue and bronchoalveolar lavage (BAL) fluid of lung transplantation 
recipients, supporting the model of an aberrant immune response (14–22). BOS diagnosis in 
allogeneic HCT recipients corresponds to a poor prognosis due to a high infection risk and 
pulmonary failure, with less than 20% survival at 5 years (2). For patients who do survive, 
progressive lung disease is often accompanied by impaired quality of life, decreased 
endurance, compromised ability to perform daily activities, and eventual oxygen 
dependence.
Currently, BOS diagnosis continues to be based on pulmonary function test (PFT) 
parameters reflecting the obstructive lung defect, particularly a decline in forced expiratory 
volume in 1 second (FEV1). For HCT recipients, the 2014 National Institutes of Health 
(NIH) consensus project on diagnostic criteria for BOS were modified from those of the 
2005 NIH consensus to increase the specificity for obstructive lung defects and attempt to 
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identify BOS earlier in its course (23). For lung transplantation recipients, similar to HCT 
recipients, a decline in FEV1 is considered consistent with the onset of BOS and may be 
confirmed by a lung biopsy showing pulmonary fibrosis (7). However, PFTs have shown 
limited value for BOS diagnosis by identifying only the most severe cases (7, 23, 24). 
Therefore, plasma proteins correlated with BOS would be extremely valuable to allow early 
diagnosis, guide treatment choices, and monitor responses.
Herein, we used a mass spectrometry-based approach as a discovery engine to 
unambiguously identify candidate plasma proteins associated with BOS in a discovery 
cohort of 58 HCT recipients. We subsequently used computational biology to characterize a 
list of high-priority protein candidates. Finally, the diagnostic value of the lead candidate, 
matrix metalloproteinase-3 (MMP-3, also called stromelysin-1), was evaluated by enzyme-
linked immunosorbent assay (ELISA) in the plasma of a verification cohort of 112 patients 
with and without BOS following HCT or lung transplantation.
 2. Methods
 2.1. Patients and samples
Three cohorts of patients were included in this study (BOS discovery, BOS verification, and 
cGVHD post-HCT verification). Patients were treated at the University of Michigan, the 
Fred Hutchinson Cancer Research Center, and the Indiana University School of Medicine. 
All patients or their legal guardians provided written informed consent, and the collection of 
samples for studying post-HCT or post-lung transplantation complications was approved by 
the institutional review boards of the University of Michigan, the Fred Hutchinson Cancer 
Research Center, and Indiana University School of Medicine. Heparinized blood samples 
were collected prospectively, either prior or at the time of the onset of symptoms consistent 
with BOS, and at matched time points post-HCT or lung transplantation in patients who did 
not develop BOS. Samples were aliquoted without additives into cryovials and stored at 
−80°C. BOS diagnosis was established after extensive testing for respiratory infections and 
PFT criteria for BOS established by the HCT and lung transplantation consensus (7, 23).
 2.2. Proteomics analysis
The proteomics methods are detailed in the Supplemental Methods in the Supporting 
Information.
 2.3. Six-step computational biology approach
The six-step computational biology approach is detailed in Supplemental Methods in the 
Supporting Information.
 2.4. ELISAs
MMP-3 antibody pairs were purchased from Bio-techne, and an FN1 ELISA kit from 
eBioscience. Samples and standards were analyzed in duplicate according to the 
manufacturer’s protocols. Briefly, capture antibody was coated in 96-well plates (Corning) 
overnight at room temperature (RT). Standards were prepared and plasma samples diluted 
(1:25) and added for 2 hours at RT while mixing on an orbital shaker. After washing, 
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biotinylated antibody was added and incubated for 2 hours. Plates were washed and 
streptavidin-conjugated horseradish peroxidase (SA-HRP) was diluted as recommended and 
added for 30 minutes. The TMB color substrate was prepared and incubated for 6 minutes. 
The reaction was terminated by addition of 1.5 M sulfuric acid, and the absorbance 
immediately determined using a SpectraMax 384plus plate reader (Molecular Devices).
 2.5. Statistical analysis
Differences in characteristics between patient groups were assessed with Student t tests for 
continuous variables and with χ2 tests for categorical variables. Logarithmic (Log2) 
transformed protein values were used in all analyses because of the skewness of the raw 
values. Median protein concentrations from individual samples in the verification cohort 
were compared using the Wilcoxon-Mann-Whitney test. p values were not corrected for 
multiple comparisons in a priori analyses. AUCs were estimated nonparametrically.
 3. Results
 3.1. Proteomics discovery
We first performed a discovery proteomics analysis comparing four pools of plasma in the 
same proteomics experiment. Pool 1 contained plasma from 12 HCT recipients who met 
BOS criteria and with plasma samples available at the onset. Pool 2 contained plasma from 
16 HCT recipients with pulmonary infections who never had BOS during their course. Pool 
3 contained plasma from 15 HCT recipients with cGVHD without pulmonary involvement 
(cGVHD no BOS), and pool 4 contained plasma from 15 HCT recipients with no chronic 
complications (plasma samples collected at a similar time point post-HCT as BOS samples). 
Each pool contained 25 µl plasma and was labeled with a unique tag [isobaric Tags for 
Relative and Absolute Quantification (iTRAQ)] allowing for differential quantification. 
Plasma pools were compared between patients with BOS versus the other three conditions. 
The clinical characteristics of patients in this discovery cohort are provided in Table S1.
The acquired liquid chromatography-tandem mass spectrometry (LC-MS/MS) data were 
analyzed using two approaches and two search engines, Proteome Discoverer™ version 1.4 
(Thermo Scientific) and Mascot™ version 2.4 (Matrix Science) (25). In the Proteome 
Discoverer analysis, a total of 857 proteins were identified with at least one peptide after 
filtering using a stringent 1% peptide-level false discovery rate (FDR; see methods), and of 
these, the levels of 855 proteins (Table S2) were quantified. Of these proteins, 21 were 
upregulated more than 1.5-fold, and 222 proteins were downregulated more than 33% in the 
BOS pool (pool 1) compared with the pool without chronic complications (pool 4). In the 
Mascot™ analysis, a total of 682 proteins were identified after filtering with a significance 
threshold of p<0.01 (see methods). Using the weighted protein abundance ratio in Mascot™, 
the protein abundance ratios were obtained for 462 (Table S3) of the 682 proteins. Of these 
proteins, 62 were upregulated more than 1.5-fold, and 65 were downregulated more than 
33% in the BOS pool (pool 1) compared with the pool without chronic complications (pool 
4). A total of 422 proteins were identified by both approaches, and of these, 5 were 
upregulated more than 1.5-fold and 52 were downregulated more than 33%.
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 3.2. Selection of lead candidates from our computational biology approach
We next applied a computational biology approach to characterize and screen BOS-specific 
proteins from the two mass-spectrometry identification results. The original number of 
proteins identified in the Proteome Discoverer™ analysis was 857 (mapped to 822 genes). 
After six steps of system biology data processing, five BOS-specific proteins were 
characterized (Table 1a and Tables S4, S6) from formed protein–protein interaction network 
module (Figure 1a). The original number of proteins identified in the Mascot™ experiment 
was 462 (mapped to 436 genes). After six steps of computational biology data processing, 
six BOS-specific proteins were characterized (Table 1b and Tables S5, S7) from formed 
protein–protein interaction network module (Figure 1b). The discrepancy between the two 
characterized network modules is due to the complexity of the mass spectrometry techniques 
and the different protein identification and quantification methods implemented in the two 
mass spectrometry data analysis software tools (see Discussion). However, two proteins, 
fibronectin 1 (FN1) and MMP-3, were consistently identified by both approaches, making 
them potential BOS-specific proteins.
 3.3. Validation of MMP-3 by ELISA in a verification cohort
We then evaluated the diagnostic potential of the candidate proteins for BOS diagnosis in a 
verification cohort of 112 transplantation recipients. The clinical characteristics of patients 
in this verification cohort combining HCT and lung transplantation are described in Table 2. 
We categorized plasma samples of the verification cohort into two different groups 
according to the presence or absence of BOS diagnosis: patients after either HCT or lung 
transplantation presenting with BOS (n=40) and patients without BOS (n=72). Plasma from 
healthy donors (n=20) was used as the reference. In patients without BOS, samples were 
obtained at equivalent time points after HCT as from patients with BOS. Recipients of grafts 
from mobilized peripheral blood (PB) or from donors who were not family members were 
overrepresented in the BOS group (26). As previously reported (27), patients who developed 
prior acute GVHD were more likely to develop cGVHD and BOS, but this was not different 
from patients with cGVHD and no BOS (Table S8).
We first analyzed plasma concentrations of both FN1 and MMP3 in a pilot study of 17 BOS 
cases versus 13 controls without BOS. FN1 was not significantly different between the two 
groups in the pilot study (Figure S1), and thus, further analysis focused on MMP3. Plasma 
MMP-3 concentrations were significantly higher in patients with BOS than in patients 
without BOS and healthy donors (p<0.0001; Figure 2A). We next generated a receiver 
operating characteristic (ROC) curve, which represents the false and true positive rates for 
every possible level of MMP3, comparing the patients with and without BOS, and found that 
the area under the ROC curve (AUC) was 0.77 (95% confidence interval: 0.68–0.86; Figure 
2B). These data show that MMP-3 is a sensitive and specific discriminator for the diagnosis 
of BOS in HCT and lung transplantation recipients who exhibit a decline in FEV1. Because 
it was also important to show that MMP-3 is a marker of BOS specifically versus cGVHD, 
we compared MMP-3 plasma concentrations in patients with BOS post-HCT (n=31) versus 
patients with cGVHD but without lung involvement (n=167). The clinical characteristics of 
patients in this cohort of only HCT recipients are described in Table S2. MMP-3 
concentrations were significantly higher in patients with BOS than in patients with cGVHD 
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without BOS (p=0.02; Figure 3) and in HCT patients without cGVHD (p<0.0001; Figure 3). 
Of note, our study was not powered to compare concentrations in patients with versus 
without BOS in the lung transplantation subgroup.
 3.4. MMP-3 plasma concentrations prior to the BOS diagnosis
We next measured the plasma concentrations of MMP-3 on timepoints prior BOS diagnosis 
in 13 HCT and 10 lung transplantation patients with BOS for whom prior onset samples 
were available, to evaluate MMP-3 plasma concentrations kinetics before the diagnosis of 
BOS (Figure 4). Measurements in longitudinal samples showed that MMP3 is not elevated 
in the plasma prior to the onset of BOS as defined by FEV1 criteria, even when the samples 
were taken closer to the diagnosis (30 to 180 days prior).
 4. Discussion
MMP-3 was identified as a candidate plasma protein specific for BOS after HCT and lung 
transplantation via an in-depth tandem MS (MS/MS)–based analysis of plasma combined 
with a multiscale computational biology process: (1) generation of abundance rate from the 
comparison of plasma samples taken from BOS and cGVHD without lung involvement, (2) 
generation of protein–protein interactions pairs in the STRING database and selection of the 
BOS-relevant proteins by the relevance score Rp, (3) computing penalty scores for 
unspecific proteins found in proteomics experiments for cancer and cardiovascular diseases, 
(4) pair-wise baseline transformation and comparison of proteins specific for BOS versus 
pulmonary infection versus cGVHD without BOS, (5) filtering out proteins found in 
proteomics experiments that are not related to BOS using domain knowledge provided by 
experts, and (6) visual exploration of the candidate list using a GeneTerrain computational 
biology visual analytic software tool (28–30). This process enabled us to reduce a list of 
hundreds of proteins to about a dozen proteins with little human selection bias. Furthermore, 
we used this approach for two separate proteomics analyses done with different protein 
search engines and selected proteins reported by both analyses with reliable quantification as 
potential candidate markers. In the identification of protein–protein interaction modules, it 
has been challenging to determine which proteins identified from proteomics results 
represent true positive signals instead of the background as contaminants. One recently 
developed approach involved generation of the Contaminant Repository for Affinity 
Purification (the CRAPome) by aggregating negative controls from multiple studies of 
affinity purification coupled with mass spectrometry (31). By filtering out unspecific 
proteins using the penalty score, we applied a similar approach that is key to increasing the 
specific relevance of the proteins identified. With our approach, we found a protein that was 
not only identified as highly relevant in two separate proteomics analyses but also in a large 
independent cohort with a high AUC. The technique used for protein detection validation 
was a sandwich ELISA that is the most relied-on approach for clinical tests because it is 
highly sensitive and specific due to the extreme affinity of two antibodies recognizing 
different epitopes from the full length of the protein (32, 33).
In this study, we favored the large scale proteomics approach as compared to the hypothesis-
driven approach because 1) an hypothesis-driven approach focusing on MMPs has been 
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performed previously in the context of BOS following lung transplantation (34), and 2) we 
hypothesize that we could find additional proteins using MS/MS proteomics that will not 
have been thought of just based on functional hypothesis as we have shown for other models 
such as acute GVHD markers (i.e. ST2, (35)). The proteomics workflow is used as a 
discovery tool for potential candidate markers; however, in this ITRAQ experiment, only one 
protein (MMP3) was validated, which is lower than numbers obtained in our previous IPAS 
experiments (35–37), in proportion to the number of proteins quantified (approximately 
2000 vs. 500, respectively). This suggests that lower sensitivity is achieved with the ITRAQ 
workflow as compared to the IPAS workflow. The mostly likely explanations for the 
differences between the ITRAQ workflow vs. the IPAS workflow are: (i) a lower plasma 
volume was processed (20–50 µl vs. 300 µl), and (ii) single-dimensional fractionation at the 
tryptic peptide level vs. two-dimensional fractionation only then followed by tryptic 
digestion. Based on the different biochemical conditions between IPAS and iTRAQ, it is 
quite possible that some classes/types of proteins could be favored in one method versus the 
other. Due to the prohibitive cost and labor intensity of multi-dimensional fractionation such 
as was done in IPAS (480 pools), we do not consider future workflows involving IPAS, and 
instead we have already taken several steps to improve the sensitivity and quantification of 
our current MS/MS workflow for future studies that include better depletion of higher 
abundant proteins, use of Tandem Mass Tag (TMT) labeling, longer LC-MS elution 
gradient, and optimizing mass spectrometry data collection.
MMPs are prominent contributors to microenvironmental signaling, because these 
proteolytic enzymes degrade structural components of the extracellular matrix (ECM), 
permitting tissue remodeling. Additionally, MMPs can release cell-bound inactive precursor 
forms of growth factors, degrade cell–cell and cell–ECM adhesion molecules, activate 
precursor zymogen forms of other MMPs, and inactivate inhibitors of MMPs and other 
proteases (38). MMP-3 in particular has been shown to promote the epithelial–mesenchymal 
transition (EMT) that can result in tissue fibrosis (39). It is important to note that MMP-3 is 
not the only protease capable of initiating EMT (39). In our study, MMP-10 (stromelysin-2) 
was also identified and upregulated in the BOS proteomics experiment but did not pass our 
six-step computational biology filtering process. In addition, to formally prove that our 
approach targeted the most biologically relevant proteins, we measured MMP-10 plasma 
concentration by ELISA and did not observe a difference in MMP-10 levels between 
patients with and without BOS (data not shown). Elevated plasma levels of MMP-9, and 
TIMP-1 have been previously associated with BOS after lung transplantation (34), but in our 
proteomics study, these proteins were identified and found increased in both BOS and 
cGVHD samples. Thus, they were not selected by our computational biology process. 
During the acute phase of GVHD, MMPs inhibitors such as TIMP-1 have been found 
elevated more often than the MMPs per se (40, 41). However, MMPs have been reported to 
be correlated with inflammation as well, and MMP-9 was shown in a small cohort of HCT 
patients to be correlated with acute GVHD (42) and that suppression of MMP-9 by a 
plasmin inhibitor attenuated murine acute GVHD (43). In our knowledge, there is no studies 
on MMPs correlated with chronic GVHD.
Few other potential biological correlates of BOS following HCT have been proposed using a 
hypothesis-driven approach such as lung epithelial proteins: Clara cell secretory protein-16 
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(44) and Serum Krebs Von Den Lungen-6 (45), or BAFF levels and CD19+CD21low B cells 
(46).
The combination of discovery proteomics analysis and computational biology is an efficient 
method for reducing a list of thousands of proteins to a short list of candidate proteins that 
can be validated by ELISA. This method combines various information sources, including 
protein quantification, protein–protein interaction networks, and domain knowledge from 
experts, making it a powerful approach for distinguishing proteins related to BOS from those 
not related. While the method successfully identified candidate proteins in this study, it still 
has weaknesses. First, the mass spectrometry-based protein identification and quantification 
analysis is not robust due to the low abundances of candidate proteins and the complexity of 
data. It is common to identify only one peptide in a candidate protein using bottom-up mass 
spectrometry because of the low abundance. As a result, “one hit wonders” in protein 
identification are often reported, which may introduce many false-positive identifications. 
This was the main reason for the discrepancies between the two protein lists reported by 
Proteome Discoverer and Mascot. Second, the filtering process heavily relies on domain 
knowledge of experts, which plays an important role in filtering out proteins that are 
commonly observed in plasma but are not related to BOS. This reliance on expert domain 
knowledge makes it difficult to apply this method to diseases that have not been well 
studied.
Although tested in a relatively small cohort, MMP-3 appears to represent a non-invasive 
blood test for diagnosis of BOS as defined by FEV1 criteria. MMP-3 plasma concentrations 
kinetics showed that MMP-3 is not elevated in the plasma prior to the onset of BOS, even 
when the samples were taken closer to the diagnosis (30 to 180 days prior) suggesting that 
MMP-3 is augmented only when FEV1 is decreased and thus represent a non-invasive aid 
for diagnosis rather than a prognostic test. If MMP-3 correlation with BOS is confirmed in 
future prospective studies and further correlated to risk for poor clinical outcomes, MMP-3 
measurement may provide opportunities for future therapeutic intervention to minimize BOS 
severity or to stabilize the disease. It has recently been shown that Fluticasone, 
Azithromycin, and Montelukast (FAM) inhalation treatment halted pulmonary decline in 
new-onset BOS after HCT in the majority of patients and permitted reductions in systemic 
steroid exposure (47). Indeed, protein levels cutoffs can be used to risk-stratify patients at 
low- or high-risk for developing BOS. As a next step, a prospective multicenter trial should 
include intervention and control strategies. High-risk patients are candidates for FAM 
treatment or additional/different treatment as soon as a diagnosis of BOS is established. In 
the near future, a targeted therapy should also be available (MMPs inhibitors are currently 
under development) (48). Low-risk patients could be randomized for a standard intervention 
versus a novel treatment with lower toxicity or more targeted therapies as proposed above. 
Plasma proteins measurement following HCT and lung transplantation will enable precision 
medicine for future clinical trials, just as protein measurement has done for other diseases 
(49).
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ELISA enzyme-linked immunosorbent assay
EMT epithelial–mesenchymal transition
FEV1 forced expiratory volume in 1 second
FN1 fibronectin 1
HCT allogeneic hematopoietic cell transplantation
iTRAQ isobaric Tags for Relative and Absolute Quantification
LC-MS/MS liquid chromatography-tandem mass spectrometry
MMP-3 matrix metalloproteinase-3
µL microLiter
NIH National Institutes of Health
n number of patients
PFT pulmonary function test
PPI protein–protein interaction
p p-value
ROC receiver operating characteristic
Rp relevance score
References
1. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. The New England journal 
of medicine. 2014; 370(19):1820–1828. [PubMed: 24806161] 
Liu et al. Page 9
Am J Transplant. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
2. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic 
hematopoietic stem cell transplantation. Jama. 2009; 302(3):306–314. [PubMed: 19602690] 
3. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic 
hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-
versus-host disease. Biology of blood and marrow transplantation : journal of the American Society 
for Blood and Marrow Transplantation. 2010; 16(1 Suppl):S106–S114.
4. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-
host disease: analysis of risk factors and treatment outcomes. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 2003; 
9(10):657–666.
5. Nishio N, Yagasaki H, Takahashi Y, Muramatsu H, Hama A, Tanaka M, et al. Late-onset non-
infectious pulmonary complications following allogeneic hematopoietic stem cell transplantation in 
children. Bone marrow transplantation. 2009; 44(5):303–308. [PubMed: 19349954] 
6. Uhlving HH, Buchvald F, Heilmann CJ, Nielsen KG, Gormsen M, Muller KG. Bronchiolitis 
obliterans after allo-SCT: clinical criteria and treatment options. Bone marrow transplantation. 
2012; 47(8):1020–1029. [PubMed: 21874057] 
7. Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, et al. An international 
ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans 
syndrome. The European respiratory journal. 2014; 44(6):1479–1503. [PubMed: 25359357] 
8. Husain AN, Siddiqui MT, Holmes EW, Chandrasekhar AJ, McCabe M, Radvany R, et al. Analysis 
of risk factors for the development of bronchiolitis obliterans syndrome. American journal of 
respiratory and critical care medicine. 1999; 159(3):829–833. [PubMed: 10051258] 
9. Nicod LP. Mechanisms of airway obliteration after lung transplantation. Proceedings of the 
American Thoracic Society. 2006; 3(5):444–449. [PubMed: 16799090] 
10. Girnita AL, Duquesnoy R, Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, et al. HLA-specific 
antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. 
American journal of transplantation : official journal of the American Society of Transplantation 
and the American Society of Transplant Surgeons. 2005; 5(1):131–138.
11. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, et al. Development of an 
antibody specific to major histocompatibility antigens detectable by flow cytometry after lung 
transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002; 74(6):799–
804. [PubMed: 12364858] 
12. Panoskaltsis-Mortari A, Tram KV, Price AP, Wendt CH, Blazar BR. A new murine model for 
bronchiolitis obliterans post-bone marrow transplant. American journal of respiratory and critical 
care medicine. 2007; 176(7):713–723. [PubMed: 17575098] 
13. Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, et al. Donor B-cell 
alloantibody deposition and germinal center formation are required for the development of murine 
chronic GVHD and bronchiolitis obliterans. Blood. 2012; 119(6):1570–1580. [PubMed: 
22072556] 
14. Charpin JM, Valcke J, Kettaneh L, Epardeau B, Stern M, Israel-Biet D. Peaks of transforming 
growth factor-beta mRNA in alveolar cells of lung transplant recipients as an early marker of 
chronic rejection. Transplantation. 1998; 65(5):752–755. [PubMed: 9521216] 
15. DiGiovine B, Lynch J, Martinez F, Flint A, Whyte R, Iannettoni M, et al. Bronchoalveolar lavage 
neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J 
Immunol. 1996; 157(9):4194–5202. [PubMed: 8892657] 
16. Iacono A, Dauber J, Keenan R, Spichty K, Cai J, Grgurich W, et al. Interleukin 6 and interferon-
gamma gene expression in lung transplant recipients with refractory acute cellular rejection: 
implications for monitoring and inhibition by treatment with aerosolized cyclosporine. 
Transplantation. 1997; 64(2):263–269. [PubMed: 9256185] 
17. Jonosono M, Fang KC, Keith FM, Turck CW, Blanc PD, Hall TS, et al. Measurement of fibroblast 
proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis 
among lung transplant recipients. The Journal of heart and lung transplantation : the official 
publication of the International Society for Heart Transplantation. 1999; 18(10):972–985.
Liu et al. Page 10
Am J Transplant. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
18. Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M, et al. Balance between alveolar 
macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung 
Transplantation Group. American journal of respiratory and critical care medicine. 1996; 153(4 Pt 
1):1431–1436. [PubMed: 8616577] 
19. Moudgil A, Bagga A, Toyoda M, Nicolaidou E, Jordan SC, Ross D. Expression of gamma-IFN 
mRNA in bronchoalveolar lavage fluid correlates with early acute allograft rejection in lung 
transplant recipients. Clinical transplantation. 1999; 13(2):201–207. [PubMed: 10202618] 
20. Riise GC, Kjellstrom C, Ryd W, Schersten H, Nilsson F, Martensson G, et al. Inflammatory cells 
and activation markers in BAL during acute rejection and infection in lung transplant recipients: a 
prospective, longitudinal study. The European respiratory journal. 1997; 10(8):1742–1746. 
[PubMed: 9272913] 
21. Ross DJ, Cole AM, Yoshioka D, Park AK, Belperio JA, Laks H, et al. Increased bronchoalveolar 
lavage human beta-defensin type 2 in bronchiolitis obliterans syndrome after lung transplantation. 
Transplantation. 2004; 78(8):1222–1224. [PubMed: 15502724] 
22. Whitehead BF, Stoehr C, Wu CJ, Patterson G, Burchard EG, Theodore J, et al. Cytokine gene 
expression in human lung transplant recipients. Transplantation. 1993; 56(4):956–961. [PubMed: 
7692639] 
23. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of 
Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-
Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biology of blood and 
marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 
2015; 21(3):389 e381–401 e381.
24. Bergeron A, Godet C, Chevret S, Lorillon G, Peffault de Latour R, de Revel T, et al. Bronchiolitis 
obliterans syndrome after allogeneic hematopoietic SCT: phenotypes and prognosis. Bone marrow 
transplantation. 2013; 48(6):819–824. [PubMed: 23208317] 
25. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein identification by 
searching sequence databases using mass spectrometry data. Electrophoresis. 1999; 20(18):3551–
3567. [PubMed: 10612281] 
26. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem 
cells versus bone marrow from unrelated donors. The New England journal of medicine. 2012; 
367(16):1487–1496. [PubMed: 23075175] 
27. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biology of blood and 
marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 
2003; 9(4):215–233.
28. You Q, Fang S, Chen JY. GeneTerrain: visual exploration of differential gene expression profiles 
organized in native biomolecular interaction networks. Information Visualization. 2008:1–12.
29. Naylor S, Chen JY. Unraveling human complexity and disease with systems biology and 
personalized medicine. Personalized medicine. 2010; 7(3):275–289. [PubMed: 20577569] 
30. Wu X, Hasan MA, Chen JY. Pathway and network analysis in proteomics. Journal of theoretical 
biology. 2014; 362:44–52. [PubMed: 24911777] 
31. Mellacheruvu D, Wright Z, Couzens AL, Lambert JP, St-Denis NA, Li T, et al. The CRAPome: a 
contaminant repository for affinity purification-mass spectrometry data. Nature methods. 2013; 
10(8):730–736. [PubMed: 23921808] 
32. Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013; 
121(4):585–594. [PubMed: 23165480] 
33. Clarke, W. Contemporary Practice in Clinical Chemistry. 2nd. AACC Press; 2011. 
34. Smith GN Jr, Mickler EA, Payne KK, Lee J, Duncan M, Reynolds J, et al. Lung transplant 
metalloproteinase levels are elevated prior to bronchiolitis obliterans syndrome. American journal 
of transplantation : official journal of the American Society of Transplantation and the American 
Society of Transplant Surgeons. 2007; 7(7):1856–1861.
35. Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of 
therapy-resistant graft-versus-host disease and death. The New England journal of medicine. 2013; 
369(6):529–539. [PubMed: 23924003] 
Liu et al. Page 11
Am J Transplant. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
36. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, Teshima T, et al. Regenerating islet-
derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011; 118(25):
6702–6708. [PubMed: 21979939] 
37. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, Coffing B, et al. Elafin is a biomarker of 
graft-versus-host disease of the skin. Science translational medicine. 2010; 2(13):13ra12.
38. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue 
remodelling. Nature reviews Molecular cell biology. 2007; 8(3):221–233. [PubMed: 17318226] 
39. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive 
oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005; 436(7047):
123–127. [PubMed: 16001073] 
40. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R, et al. A biomarker panel 
for acute graft-versus-host disease. Blood. 2009; 113(2):273–278. [PubMed: 18832652] 
41. Salmela MT, Karjalainen-Lindsberg ML, Jeskanen L, Saarialho-Kere U. Overexpression of tissue 
inhibitor of metalloproteinases-3 in intestinal and cutaneous lesions of graft-versus-host disease. 
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, 
Inc. 2003; 16(2):108–114.
42. Tagami K, Yujiri T, Takahashi T, Kizuki N, Tanaka Y, Mitani N, et al. Increased serum levels of 
matrix metalloproteinase-9 in acute graft-versus-host disease after allogeneic haematopoietic stem 
cell transplantation. International journal of hematology. 2009; 90(2):248–252. [PubMed: 
19548069] 
43. Sato A, Nishida C, Sato-Kusubata K, Ishihara M, Tashiro Y, Gritli I, et al. Inhibition of plasmin 
attenuates murine acute graft-versus-host disease mortality by suppressing the matrix 
metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking. 
Leukemia. 2015; 29(1):145–156. [PubMed: 24791857] 
44. Mattsson J, Remberger M, Andersson O, Sundberg B, Nord M. Decreased serum levels of clara 
cell secretory protein (CC16) are associated with bronchiolitis obliterans and may permit early 
diagnosis in patients after allogeneic stem-cell transplantation. Transplantation. 2005; 79(10):
1411–1416. [PubMed: 15912112] 
45. Gassas A, Schechter T, Krueger J, Craig-Barnes H, Sung L, Ali M, et al. Serum Krebs Von Den 
Lungen-6 as a Biomarker for Early Detection of Bronchiolitis Obliterans Syndrome in Children 
Undergoing Allogeneic Stem Cell Transplantation. Biology of blood and marrow transplantation : 
journal of the American Society for Blood and Marrow Transplantation. 2015; 21(8):1524–1528.
46. Kuzmina Z, Krenn K, Petkov V, Kormoczi U, Weigl R, Rottal A, et al. CD19(+)CD21(low) B cells 
and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans 
syndrome. Blood. 2013; 121(10):1886–1895. [PubMed: 23303823] 
47. Williams KM, Cheng GS, Pusic I, Jagasia M, Burns L, Ho VT, et al. Fluticasone, Azithromycin, 
and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after 
Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the 
American Society for Blood and Marrow Transplantation. 2015
48. Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase 
inhibition? Nature reviews Drug discovery. 2014; 13(12):904–927. [PubMed: 25376097] 
49. Jameson JL, Longo DL. Precision Medicine - Personalized, Problematic, and Promising. The New 
England journal of medicine. 2015
Liu et al. Page 12
Am J Transplant. Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. a, Biomarker selection via gene terrain visualization tools shown in a 2D panel obtained 
with the Proteome Discoverer™ proteomics analysis; b, biomarker selection via gene terrain 
visualization tools shown in a 2D panel obtained with the Mascot™ proteomics analysis
MMP-3: matrix metalloproteinase-3; FN1: fibronectin; VWF: von Willebrand factor; 
TIMP1: Metalloproteinase inhibitor 1; TIMP2: Metalloproteinase inhibitor 2; CD44: CD44 
antigen; CSF1R: Macrophage colony-stimulating factor 1 receptor; KIT: Mast/stem cell 
growth factor receptor Kit; LRG1: Leucine-rich alpha-2-glycoprotein.
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Figure 2. a, MMP-3 plasma concentrations measured by ELISA in the BOS verification cohort; 
b, ROC curve comparing patients with and without BOS post-transplantation
a. Individual log2 transformed MMP-3 in ng/ml are plotted for BOS patients (n = 41), no 
BOS patients (n = 71), and healthy donors (n = 20). Wilcoxon-Mann-Whitney test 
comparing the median of BOS vs. no BOS, p<0.0001. b. Area under the ROC = 0.77.
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Figure 3. MMP-3 plasma concentrations measured by ELISA in an HCT cohort of patients with 
cGVHD not of the lung and with BOS post-HCT
Individual log2 transformed MMP-3 in ng/ml are plotted for BOS patients (n = 31), no BOS 
with cGVHD patients (n = 167), and no BOS no cGVHD patients (n = 45). Wilcoxon-Mann-
Whitney test comparing the median: BOS vs. cGVHD, p=0.02; BOS vs. BOS no cGVHD, 
p<0.0001.
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Figure 4. MMP-3 plasma concentration kinetics prior to BOS diagnosis in 13 HCT and 10 lung 
transplantation patients
Individual log2 transformed MMP-3 in ng/ml are graphed at >180 days, 30 to 180 days prior 
to and at the BOS diagnosis. The bold line represents the mean of the cohort.
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